Please type a plus sign (+) inside this box -> +

PTO/SB/81 (02-01)
Approved for use through 10/31/2002. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCI by the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY OR

AUTHORIZATION OF AGENT

16	equired to respond to a collection of inform	lation unless it displays a valid OMB control number.
	Applicati n Number	09/580,015
ı	Filing Date	May 26, 2000
ı	First Named Inventor	Dale B. Schenk
	Title	PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
ı	Group Art Unit	1641
	Examiner Name	Unassigned.
	Attorney Docket Number	15270J-004750US

I hereby a	ppoint:						
		tomer Number	20350			Place Customer Number Bar Code Label here	SEP 2 1 2001 TECH CENTER 1600/2900
B	oner(s) name	ed below:			1		一分
[Name	· · · · · · · · · · · · · · · · · · ·		Registration	on Number	40 35 35
						· · · · · · · · · · · · · · · · · · ·	型 2
l t				_			国山
1							70
L as my/our a	tomov(a) or	agant(a) to proc	auto the englication	idontific	d above, and to	eranant all	8 2
			ecute the application Trademark Office o			ransact all	290
! <u></u>			ess for the above-ide	entified a	pplication to:		
OR	ve-mentione	d Customer Num	ber.				
I <u></u> -	ners at Custo	omer Number			—	•	
					······································		
Firm <i>or</i>	al Name						
Address							
Address							
City				State		ZIP	
Country							
Telephone				Fax			
I am the:		<u></u>					
Applica	ant/Inventor.						
Assign	ee of record	l of the entire inte	rest. See 37 CFR 3	3.71.			
Statem	ent under 37	7 CFR 3.73(b) is	enclosed. (Form PT	O/SB/96)			
		SIG	NATURE of Applica	ant or A	ssignee of Reco	rd	
Name	Neuralab L	imited, by: Kevi	n Insley, Vice Presid	ent			
Signature		thatts	Trul				
Date	Au	GUST 31	,20011				
NOTE: Signa	tures of all	the inventors or	assignees of recor	d of the	entire interest o	r their representative	(s) are required.
X *Total of	<u>1</u> form is su	ibmitted.	ignature is required	u, see De	HOW".		

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3167760 v1

~~ 4 0 2001 Ed	n (+) inside this box	U.S. Patent and Tra	PTO/SB/81 (02-01) pproved for use through 10/31/2002. OMB 0851-0035 idemark Office; U.S. DEPARTMENT OF COMMERCE nation unless it displays a valid OMB control number.
	<u> </u>	Application Number	09/580,015
FIFAT & THAU THEFT		Filing Date	May 26, 2000
1	OF ATTORNEY OR	First Named Inventor	Dale B. Schenk
	ZATION OF AGENT	Title	PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
,		Group Art Unit	1641
		Examiner Name	Unassigned.
		Attorney Docket Number	15270J-004750US
I bereby appoi	nt·		

I hereby ap	point:				ſ	Place Customer	\neg
☐ Practition	ners at Cu	stomer Number			 ▶	Place Customer Number Bar Code Label here	
☑ Practition	ner(s) nam	ned below:			'		_
Į.		Name			Registration	on Number	#
		Nina M. Asht	ton		37,	273	S. E.
		Jean M. Duv	all		32,	731	A 4
		Lisabeth F. Mu	rphy		31,	547	
ľ							兴
as my/our a business in	ttorney(s) o	or agent(s) to prosect States Patent and Ti	ute the application rademark Office o	identified onnected t	above, and to herewith.	transact all	TECH CENTER 1600/2900
The abov	ve-mention	respondence addressed Customer Numberstomer Number		entified app	plication to:	•	9
Firm or	al Name						
Address							
Address							
City				State		ZIP	
Country							
Telephone				Fax			····
I am the:							
☐ Applic	ant/Invento	or.					
		ord of the entire intere					
Statem	ent under .	37 CFR 3.73(b) is en	iclosed. (Form PT	O/SB/96).			
		SIGN	ATURE of Applic	ant or Ass	signee of Rec	ord	
Name	Neuralab	Limited, by: Kevin	Insley, Vice Presi	dent			
Signature		Cato	ismelf	//			
Date	A	19UST 31.	200/				
NOTE: Signa	atures of a	all the inventors or a if more than one sig	ıssignees of [/] recoi	rd of the e	entire interest o	or their representative	(s) are required.
Submit multi			griature is require	u, see bei			

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3167776 v1

PTO/SB/96 (08-00)
Approved for through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Attorney Docket No. 15270 L004750110

STATEMENT UNDER 37 CFR 3.73(b)	
Applicant/Patent Owner: Dale B. Schenk	
Application No./Patent No.: 09/580,015 Filed/Issue Date: May 26, 2000 Entitled: PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE	
Neuralab Limited , a <u>corporation</u> (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)	
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)	\wedge
states that it is:	
1. the assignee of the entire right, title, and interest; or	, , , \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
2. an assignee of an undivided part interest	
in the patent application/patent identified above by virtue of either:	12 2 Z
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.	AKCKINEH TOOLOO
OR	(19)
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:	
From: Dale B. Schenk To: Elan Pharmaceuticals, Inc. The document was recorded in the United States Patent and Trademark Office at Reel 011203, Frame 0648, or for which a copy thereof is attached.	:
From: Elan Pharmaceuticals, Inc. To: Neuralab Limited The document was recorded in the United States Patent and Trademark Office at Reel 011203, Frame 0488, or for which a copy thereof is attached.	
3. From: To :	
The document was recorded in the United States Patent and Trademark Office at	
Reel, Frame, or for which a copy thereof is attached.	
Additional documents in the chain of title are listed on a supplemental sheet.	
Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]	
The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.	
September 1, 2001 LATTSWALL	
Date Signature	
Kevin Insley	
Typed or printed name	
Vice President	
Title	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

irst Named Inventor roup Art Unit xaminer Name ttorney Docket Numb IRES (check all that app at Papers ication) related Papers puting Slip (PTO/SB/69) appanying Petition Convert to a I Application of Attorney (PTO/SB/81) o. 20350) & (to Ashton, rphy) isclaimer r Refund er of CD(s) The Commissioner	1641 Unassigned ber 15270J-004750US After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter
iroup Art Unit xaminer Name ttorney Docket Number IRES (check all that app int Papers ication) related Papers puting Slip (PTO/SB/69) inpanying Petition Convert to a il Application of Attorney (PTO/SB/81) io. 20350) & (to Ashton, riphy) isclaimer ir Refund er of CD(s) The Commissioner	1641 Unassigned ber 15270J-004750US After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): 1. Statement Under 37 CFR 3.73(b) (PTO/SB/96) (1 page); and,
xaminer Name Ittorney Docket Number IRES (check all that application) Int Papers ication) Intelleted Papers Intelleted Pap	Unassigned ber 15270J-004750US After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): 1. Statement Under 37 CFR 3.73(b) (PTO/SB/96) (1 page); and,
ttorney Docket Number RES (check all that appoint Papers ication) related Papers soluting Slip (PTO/SB/69) inpanying Petition Convert to a I Application of Attorney (PTO/SB/81) io. 20350) & (to Ashton, riphy) isclaimer ir Refund er of CD(s) The Commissioner	Der 15270J-004750US After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): Statement Under 37 CFR 3.73(b) (PTO/SB/96) (1 page); and,
IRES (check all that appoint Papers ication) related Papers puting Slip (PTO/SB/69) panying Petition Convert to a I Application of Attorney (PTO/SB/81) o. 20350) & (to Ashton, rphy) isclaimer r Refund er of CD(s) The Commissione	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): Statement Under 37 CFR 3.73(b) (PTO/SB/96) (1 page); and,
related Papers relate	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): Statement Under 37 CFR 3.73(b) (PTO/SB/96) (1 page); and,
related Papers related PTO/SB/69) relation	Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): Statement Under 37 CFR 3.73(b) (PTO/SB/96) (1 page); and,
related Papers outing Slip (PTO/SB/69) opanying Petition Convert to a I Application of Attorney (PTO/SB/81) o. 20350) & (to Ashton, rphy) isclaimer r Refund er of CD(s) The Commission	Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): Statement Under 37 CFR 3.73(b) (PTO/SB/96) (1 page); and,
outing Slip (PTO/SB/69) npanying Petition Convert to a I Application of Attorney (PTO/SB/81) o. 20350) & (to Ashton, rphy) isclaimer r Refund er of CD(s) The Commission	(Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): Statement Under 37 CFR 3.73(b) (PTO/SB/96) (1 page); and,
npanying Petition Convert to a I Application of Attorney (PTO/SB/81) o. 20350) & (to Ashton, rphy) isclaimer r Refund er of CD(s) The Commission	Status Letter Other Enclosure(s) (please identify below): 1. Statement Under 37 CFR 3.73(b) (PTO/SB/96) (1 page); and,
Application of Attorney (PTO/SB/81) o. 20350) & (to Ashton, rphy) isclaimer r Refund er of CD(s) The Commission	Other Enclosure(s) (please identify below): 1. Statement Under 37 CFR 3.73(b) (PTO/SB/96) (1 page); and,
o. 20350) & (to Ashton, rphy) isclaimer r Refund er of CD(s) The Commission	(please identify below): 1. Statement Under 37 CFR 3.73(b) (PTO/SB/96) (1 page); and,
r Refund er of CD(s) The Commission	(PTO/SB/96) (1 page); and,
er of CD(s) The Commissione	2. Return Postcard.
The Commission	
Deposit Account	ner is authorized to charge any additional fees t 20-1430.
LICANT, ATTORNE	Y, OR AGENT
	eg No. 42,397
7 - 0	1 ~
J. Cil	L
ICATE OF MAILING	G
	ILLP Re

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3168539 v1